Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Deferred Revenue (2019 - 2026)

Biodesix filings provide 8 years of Current Deferred Revenue readings, the most recent being $200000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 74.62% to $200000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $200000.0, a 74.62% decrease, with the full-year FY2025 number at $1.0 million, up 42.86% from a year prior.
  • Current Deferred Revenue hit $200000.0 in Q1 2026 for Biodesix, down from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.8 million in Q3 2025 to a low of $200000.0 in Q1 2026.
  • Median Current Deferred Revenue over the past 5 years was $788000.0 (2025), compared with a mean of $1.1 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 314.2% in 2025 and later tumbled 74.62% in 2026.
  • Biodesix's Current Deferred Revenue stood at $962000.0 in 2022, then tumbled by 66.32% to $324000.0 in 2023, then skyrocketed by 116.05% to $700000.0 in 2024, then soared by 42.86% to $1.0 million in 2025, then crashed by 80.0% to $200000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $200000.0 (Q1 2026), $1.0 million (Q4 2025), and $2.8 million (Q3 2025) per Business Quant data.